Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

@inproceedings{Canonici2013NeratinibOT,
  title={Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer},
  author={Alexandra Canonici and Merel Gijsen and Maeve Mullooly and Ruth Bennett and Noujoude Bouguern and Kasper Pedersen and Neil A. O'Brien and Ioannis Roxanis and Ji-liang Li and Esther Bridge and Richard S. Finn and Dennis J. Slamon and Patricia M. McGowan and Michael J. Duffy and Norma O'Donovan and John P. A. Crown and Anthony Kong},
  booktitle={Oncotarget},
  year={2013}
}
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer cell lines. We further assessed its effects with or without trastuzumab in several sensitive and resistant breast cancer cells as well as a BT474 xenograft model. We… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Neratinib: First Global Approval

Drugs • 2017
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 1 Excerpt

A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2positive breast cancer, NSABP FB-8

RC Jankowitz, J Abraham, +5 authors N. Wolmark
J Clin Oncol • 2012
View 1 Excerpt

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…